+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 3Years +
All Genders
ID07294547

Comparing Valacyclovir and Valganciclovir for Preventing CMV and EBV Infections in Kidney Transplant Patients A Prospective Randomized Pilot Study at a Single Center

Led by National Taiwan University Hospital · Updated on 2025-12-19

80

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of valacyclovir compared with valganciclovir as preventive treatment for cytomegalovirus CMV and Epstein-Barr virus EBV infections in kidney transplant recipients. These infections commonly occur in immunosuppressed patients early after transplant or during intensified immunosuppression for rejection. Valganciclovir is effective but can cause bone marrow suppression and kidney toxicity, while valacyclovir may have fewer side effects and lower cost. This pilot study aims to assess if valacyclovir is not worse than valganciclovir in preventing CMV and EBV viremia in both pediatric and adult patients. Participants will be randomly assigned to receive either valacyclovir or valganciclovir as antiviral prophylaxis. Adults in the valacyclovir group will take 1000 mg twice daily, while pediatric doses are weight-based up to 1000 mg twice daily. The valganciclovir group will receive 450 mg once daily for adults and weight-based doses up to 450 mg once daily for children. Dosages will be adjusted for kidney function. Treatment will last at least six months, and pediatric patients unable to swallow pills may receive valganciclovir suspension. During the study, participants will have regular clinic visits for viral load testing and monitoring of side effects for up to two years. The main outcomes measured are the time to new CMV and EBV viremia and their incidence at 6 months, 1 year, and 2 years. Secondary outcomes include bone marrow suppression, kidney function decline, other adverse events, and viral load levels. This study will provide important information for future larger trials and may influence post-transplant antiviral protocols.

CONDITIONS

Brief Title

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

Research Team

H

Hou-Xuan Huang, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here